Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Verde Servicos Internacionais S.A.

Verde Servicos Internacionais S.A. reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.5% during the 4th quarter, Holdings Channel reports. The fund owned 13,358 shares of the medical research company’s stock after selling 3,877 shares during the quarter. Thermo Fisher Scientific comprises 3.0% of Verde Servicos Internacionais S.A.’s portfolio, making the stock its 15th largest holding. Verde Servicos Internacionais S.A.’s holdings in Thermo Fisher Scientific were worth $6,949,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in TMO. Legacy Investment Solutions LLC bought a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $26,000. Peterson Financial Group Inc. bought a new position in Thermo Fisher Scientific during the third quarter valued at about $27,000. Missouri Trust & Investment Co bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Endeavor Private Wealth Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $30,000. Finally, Decker Retirement Planning Inc. acquired a new position in Thermo Fisher Scientific in the fourth quarter worth approximately $43,000. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,850 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the completion of the sale, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,611,804.88. The trade was a 4.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 34,850 shares of company stock valued at $19,123,197 over the last 90 days. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

TMO opened at $583.43 on Tuesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The company’s 50 day simple moving average is $533.60 and its 200-day simple moving average is $569.81. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The stock has a market capitalization of $223.16 billion, a P/E ratio of 36.58, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback plan on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is currently 9.78%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Evercore ISI cut their price objective on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Bernstein Bank upped their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 22nd. Finally, TD Cowen increased their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.